Free Newsletter
Painkiller risk goes beyond Vioxx
Free newsletter via e-mail
Tools
Taking painkillers could place patients at risk for more cardiac problems or even death if they've already suffered a heart attack or have heart failure, according to a study by Danish researchers.
The researchers presented data at the American Heart Association meeting in New Orleans showing that patients taking any of several non-steroidal anti-inflammatory medications were at increased risk of heart attack or death. Patients taking generic ibuprofen had 1.3 times the risk; patients taking the generic diclofenac had 1.9 times the risk; patients taking Pfizer's Celebrex had twice the risk; and patients who had taken the now-withdrawn Vioxx had 2.7 times the risk of death or another heart attack.
At least one of the researchers recommended that physicians now avoid these types of painkillers, or use low doses, in patients with a history of heart attack or heart failure.
- read the story in the New York Times
Related Articles:
NJ Supremes to hear Vioxx preemption claims
Vioxx defense dealt a blow by new study results
Pfizer reaches $894M painkiller settlement
Fatal drug errors spike at home
Comments
By Never Mind | Posted 10:49pm | November 14, 2008
Ya and as the time passes, many of the person's who suffered a heart attack or stroke are still waiting for there points as if they are lucky. The whole vioxx settlement has seemed to have been too little to late, and it just keeps getting worse as more test results come out on the use of vioxx. It would seem that a mandatory payment above the clams adjuster's would be enforced bye the FDA congress and all involved. What is next with this drug ? and you settled for how much ? 200k to 400k seems so little, for the lose many have adsorbed in medical damages and or the lose of a loved one. ps... for all you that post in the support of big Pharma SHAME On YOU.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
